Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the Company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection (HCV) in its ongoing Phase 1 clinical trial. Proof-of-concept results from this trial are expected to be reported during the fall of 2014. Furthermore, Achillion announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on sovaprevir, an NS3/4A protease inhibitor, to permit the conduct of trials in patients with HCV. Sovaprevir doses of 200 mg once daily, the previously evaluated dose that was well-tolerated with clinical activity in two completed Phase 2 studies, may be used in additional therapeutic clinical trials. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock opened today at $6.06 and is currently trading at $6.31. The stock showed a positive weekly performance of 52.88%.
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) announced that COMPASS, its Phase IIIb clinical trial comparing the efficacy and safety of the investigational product AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraines in adults, met the primary efficacy endpoint. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath Powered™ delivery technology. In March 2014, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) of AVP-825 and the Prescription Drug User Fee Act (PDUFA) V goal date is November 26, 2014. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) stock opened at $5.58, in current trading session and currently is at $5.40, by gaining 1.12%. The 52 week range of $2.62 – $6.00. Company’s market capitalization is $860.95 billion.
U.S. womenswear chain Chico’s FAS, Inc. (NYSE:CHS)’s has held talks with several private equity firms in recent weeks about a potential sale, the Financial Times reports, citing sources. One industry source believes the company would command a premium of about 30% to its market capitalization of $2.36B. It is unclear whether Chico’s management would look to partner with a private equity group or sell the entire business. Chico’s FAS, Inc. (NYSE:CHS) stock is open at $16.71 and currently trading at $16.85. The EPS of the stock is 0.36. Company’s market capitalization is $2.58 billion.
On June 9, 2014, Alcobra Ltd (NASDAQ:ADHD), will be a featured speaker and presenter at the 2014 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) 2014 Annual Meeting, being held June 16-19, 2014 at the Westin Diplomat Hotel in Hollywood, Florida. Alcobra Ltd (NASDAQ:ADHD) stock opened the session at $17.68, and now is at $17.81. The 52 week range of the ADHD stock remained $6.50 – $26.96 and the day range was $17.68 – $17.81.
Cognizant Technology Solutions Corp (NASDAQ:CTSH) CAO Steven Schwartz sold 6,647 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $49.79, for a total transaction of $330,954.13. Cognizant Technology Solutions Corp (NASDAQ:CTSH) stock is open at $48.80 and currently trading at $48.28. The EPS of the stock is 2.12. Company’s market capitalization is $29.40 billion.